Skip to content

JCCG EPN23: A phase2 study to evaluate the efficacy and safety of the multimodality therapy using treatment stratification in pediatric ependymoma

JCCG EPN23: A phase2 study to evaluate the efficacy and safety of the multimodality therapy using treatment stratification by resection rate and molecular markers in pediatric ependymoma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041240110
Enrollment
100
Registered
2024-10-23
Start date
2024-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracranial ependymoma intracranial ependymoma

Interventions

Surgical resection, chemotherapy, radiotherapy
Neurosurgery, Induction Chemotherapy, Radiotherapy

Sponsors

Saito Ryuta
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Tumor removal or biopsy for the primary lesion is performed at the time of first occurrence, and the pathological diagnosis of ependymoma is obtained in each institution, and specimens are scheduled to be sent to the central pathology. 2) Registered in the observational study for pediatric solid tumors by Japan Children's Oncology Group (JCCG). 3) Less than 30 years old. 4) Written informed consent is obtained from the patient or his/her legal guardian.

Exclusion criteria

Exclusion criteria: 1) Active double cancer (synchronous double cancer and metachronous double cancer with disease-free period of 5 years or less). 2) Complicated heart disease requiring treatment. 3) Pregnant or nursing. 4) Cases in which the radiologist considers that it is difficult to perform radiotherapy as specified in the protocol. 5) Judgement of inappropriate inclusion by physician

Design outcomes

Primary

MeasureTime frame
Stratum 1: Non unresectable recurrence rate Stratum 2: Event-free survival (EFS) in 2 years Stratum 3: Total removal/Complete response Rate

Secondary

MeasureTime frame
Assessment of Efficacy Assessment of Safety

Contacts

Public ContactRieko Taniguchi

Shizuoka Cancer Center

r.taniguchi@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026